Overview
Mermaid diagram (expand to render)
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an Israeli biotechnology company headquartered in Petah Tikva, Israel, developing innovative small molecule drugs for the treatment of cancer, inflammatory diseases, and neurodegenerative conditions. Founded in 1994, Can-Fite has established itself as a pioneer in adenosine receptor pharmacology, with a particular focus on the A3 adenosine receptor (A3AR) as a therapeutic target across multiple disease areas.
The company's proprietary platform leverages the unique pharmacology of A3AR targeting, which offers several advantages over traditional drug development approaches. Unlike many therapeutic targets that are broadly expressed throughout the body, A3AR demonstrates differential expression patterns that enable selective targeting of pathological cells while sparing normal tissues["@a3ar_brain"]. This selectivity forms the foundation of Can-Fite's drug development strategy and differentiates its pipeline from competitors in the neurodegeneration space.
Can-Fite's neuroprotection program represents a significant expansion of the company's therapeutic focus beyond its oncology roots. The company's lead compounds have demonstrated preclinical efficacy in models of Alzheimer's disease and Parkinson's disease, and clinical development is advancing across multiple indications["@a3ar_neuroprotection"].
Corporate Profile
| Attribute | Details |
|-----------|---------|
| Headquarters | Petah Tikva, Israel |
| Founded | 1994 |
| Ticker | CANF (NYSE American) |
| Exchange | NYSE American |
| Focus | Oncology, inflammation, neurodegenerative diseases |
| Employees | ~30-50 |
| Market Cap | ~$30-50 million |
| CEO | Dr. PN (Please verify) |
| Listed | 2010 |
Can-Fite's proprietary platform is based on A3 adenosine receptor (A3AR) targeting. A3AR is a G protein-coupled receptor (GPCR) that is highly expressed in:
- Inflammatory cells (activated macrophages, neutrophils)
- Cancer cells (various solid tumors)
- Neuronal and glial cells (implicated in neurodegeneration)[@a3ar_expression]
The A3AR represents an attractive drug target for several reasons:
Differential Expression: A3AR is overexpressed in pathological cells compared to normal cells, enabling selective targeting[@a3ar_brain]
Well-Characterized Signaling: The receptor signals through Gi/o proteins, leading to modulation of cAMP, PKA, and downstream effectors
Small Molecule Tractability: Agonists and antagonists with favorable drug-like properties have been developed
CNS Penetration: Certain A3AR ligands can cross the blood-brain barrier, enabling treatment of CNS disorders[@blood_brain_barrier]Mechanism of Action
A3AR agonists exert their effects through multiple interconnected pathways:
Anti-inflammatory Effects:
- Inhibition of pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
- Modulation of macrophage polarization toward anti-inflammatory (M2) phenotype
- Reduction of neutrophil infiltration
- Suppression of NF-κB signaling pathway[@neuroinflammation_ad]
Neuroprotective Effects:
- Protection against amyloid-beta toxicity in Alzheimer's disease models[@amyloid_beta_inflammation]
- Preservation of dopaminergic neurons in Parkinson's disease models[@dopamine_neurons]
- Mitochondrial protection and anti-apoptotic signaling[@mitochondrial_protection]
- Reduction of neuroinflammation through cytokine modulation[@cytokine_reduction]
Can-Fite's A3AR platform offers several competitive advantages:
| Advantage | Description |
|-----------|-------------|
| Selective Targeting | Pathological cells overexpress A3AR, enabling preferential drug uptake |
| Multi-target Effects | Single compound affects inflammation, cell survival, and mitochondrial function |
| Oral Bioavailability | Small molecule agonists can be delivered orally |
| BBB Penetration | Selected compounds cross the blood-brain barrier |
| Established Safety | Clinical data from oncology trials supports safety profile |
Pipeline
Piclidenoson (CF101) — Lead Neurodegeneration Program
Piclidenoson (CF101) is Can-Fite's lead clinical candidate and represents one of the most advanced A3AR agonists in development for neurodegenerative diseases.
Properties:
- Chemical Class: Small molecule A3AR agonist
- Route of Administration: Oral
- Development Stage: Phase 2 (Alzheimer's disease), Phase 3 (Dry Eye Disease)
- Mechanism: A3AR agonist with potent anti-inflammatory and neuroprotective properties
Clinical Development
Piclidenoson has been evaluated in multiple clinical trials across different indications, generating safety and efficacy data that support its advancement in neurodegeneration:
Phase 2 in Alzheimer's Disease:
The company has conducted Phase 2 clinical trials evaluating piclidenoson in patients with Alzheimer's disease. These trials assess cognitive endpoints, biomarkers of neuroinflammation, and safety parameters[@clinical_trials_ad].
Phase 3 in Dry Eye Disease:
Parallel development in ophthalmology provides additional safety data and validates the anti-inflammatory mechanism of A3AR agonism.
Preclinical Neuroprotection Data
Piclidenoson has demonstrated neuroprotective effects in multiple preclinical models of neurodegenerative disease[@preclinical_ad_models]:
Alzheimer's Disease Models:
- Reduced neuroinflammation in amyloid-beta treated neuronal cultures
- Decreased pro-inflammatory cytokine production in microglia
- Protection against amyloid-beta induced toxicity
- Improved cognitive performance in animal models
Parkinson's Disease Models:
- Preservation of dopaminergic neurons in toxin-induced models
- Reduced neuroinflammation in the substantia nigra
- Improved motor function in animal studies
Mechanism in Neurodegeneration
Piclidenoson's neuroprotective effects in Alzheimer's disease operate through multiple mechanisms[@a3ar_alzheimer]:
Neuroinflammation Reduction: A3AR activation on microglia leads to reduced production of pro-inflammatory cytokines, dampening the chronic neuroinflammatory response that drives disease progression[@neuroinflammation_ad].
Amyloid-beta Modulation: Preclinical data suggests that A3AR agonism can influence amyloid processing, potentially reducing the accumulation of toxic amyloid-beta species.
Anti-apoptotic Signaling: Activation of A3AR triggers pro-survival signaling pathways that protect neurons from various toxic insults[@a3ar_apoptosis].
Mitochondrial Protection: A3AR agonists help preserve mitochondrial function in neurons, maintaining cellular energy homeostasis and preventing apoptotic cell death[@mitochondrial_protection].Namodenoson (CF102)
Namodenoson (CF102) is Can-Fite's second A3AR agonist in clinical development, with a focus on liver diseases and neuroprotection.
Properties:
- Chemical Class: Small molecule A3AR agonist
- Indication: Hepatocellular carcinoma, NASH, Neurodegeneration
- Development Stage: Phase 2
- Mechanism: A3AR agonist with anti-apoptotic and anti-inflammatory properties[@namodenoson_cf102]
Neurodegeneration Potential
Although primarily developed for liver diseases, namodenoson's A3AR agonist mechanism suggests potential for neuroprotection:
- Anti-apoptotic effects through modulation of apoptotic pathways
- Anti-inflammatory activity in peripheral and central compartments
- Potential for combination approaches in neurodegeneration
CF602
CF602 is a preclinical A3AR antagonist being developed for inflammatory conditions.
Properties:
- Chemical Class: Small molecule A3AR antagonist
- Indication: Inflammatory conditions
- Development Stage: Preclinical
- Mechanism: A3AR antagonist blocking pro-inflammatory signaling
While primarily targeting peripheral inflammation, CF602 represents the company's strategy to explore both agonist and antagonist approaches depending on disease context.
Science and Therapeutic Rationale
A3 Adenosine Receptor in Neurodegeneration
The A3 adenosine receptor has emerged as a compelling therapeutic target for neurodegenerative diseases based on substantial preclinical and clinical evidence[@a3ar_neuroprotection].
Receptor Biology
A3AR is a G protein-coupled receptor that is differentially expressed in various tissue types. In the central nervous system, A3AR is expressed on neurons, astrocytes, and microglia, where it modulates multiple cellular functions[@a3ar_brain].
Expression Patterns:
- Neurons: Moderate expression, with higher levels in certain brain regions
- Microglia: High expression, particularly in activated states
- Astrocytes: Variable expression depending on brain region and disease state
- Peripheral Immune Cells: High expression on activated macrophages and neutrophils
Signaling Pathways
A3AR activation triggers multiple intracellular signaling cascades[@neuroprotection_mechanisms]:
A3AR Activation
↓
Gi/o Protein Coupling
↓
↓ cAMP PKC Activation
↓
Anti-apoptotic Signaling (p-Akt, Bcl-2)
↓
Mitochondrial Protection
↓
Neuroprotection
Key Signaling Outcomes:
- Decreased cAMP levels through Gi/o inhibition
- Activation of PKC isoforms
- PI3K/Akt pathway activation
- MAPK pathway modulation
- NF-κB pathway inhibition
Neuroinflammation in Alzheimer's Disease
Neuroinflammation represents a central pathological feature of Alzheimer's disease and a key therapeutic target for A3AR agonists[@neuroinflammation_ad].
Inflammatory Cascade
In Alzheimer's disease, the accumulation of amyloid-beta triggers a chronic neuroinflammatory response:
Microglial Activation: Amyloid-beta aggregates activate microglia through pattern recognition receptors
Cytokine Release: Activated microglia release pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
Neuronal Dysfunction: Inflammatory mediators impair synaptic function and neuronal survival
Disease Progression: Chronic inflammation accelerates neurodegenerative processesA3AR Agonist Effects
A3AR agonists interrupt this inflammatory cascade at multiple points[@amyloid_beta_inflammation]:
- Direct Microglial Modulation: A3AR activation on microglia reduces pro-inflammatory cytokine production
- Cytokine Reduction: Systemic reduction of circulating inflammatory mediators
- Neuronal Protection: Anti-apoptotic effects preserve neuronal function
- BBB Protection: Reduced endothelial inflammation maintains blood-brain barrier integrity
Parkinson's Disease and A3AR
In Parkinson's disease, A3AR agonists offer neuroprotection through complementary mechanisms[@a3ar_parkinson]:
Dopaminergic Neuron Protection
The primary pathological feature of Parkinson's disease is the loss of dopaminergic neurons in the substantia nigra pars compacta. A3AR agonists protect these neurons through:
Anti-inflammatory Effects:
- Reduction of microglial activation in the substantia nigra
- Decreased cytokine production that contributes to neuronal death
- Modulation of neuroimmune interactions[@neuroimmune]
Anti-apoptotic Effects:
- Activation of pro-survival signaling pathways
- Preservation of mitochondrial function
- Direct protection against toxin-induced cell death
Preclinical Evidence:
Multiple preclinical studies have demonstrated that A3AR agonists can:
- Protect dopaminergic neurons from 6-OHDA toxicity
- Preserve tyrosine hydroxylase positive neurons
- Improve motor function in animal models
- Reduce neuroinflammation in the substantia nigra
Mitochondrial Protection
Mitochondrial dysfunction is a common feature of neurodegenerative diseases, and A3AR agonists have demonstrated mitochondrial protective effects[@mitochondrial_protection]:
Mechanisms:
- Preservation of mitochondrial membrane potential
- Protection against mitochondrial permeability transition
- Enhancement of mitochondrial biogenesis
- Reduction of reactive oxygen species (ROS) production
- Prevention of cytochrome c release
These effects are particularly relevant for neuronal survival, as neurons are highly dependent on mitochondrial function for energy production and cellular homeostasis.
Clinical Development Strategy
Alzheimer's Disease Program
Can-Fite's Alzheimer's disease program aims to develop disease-modifying therapies that target the underlying pathophysiology rather than just symptoms.
Development Approach:
Phase 1: Single and multiple ascending dose studies to establish safety and tolerability
Phase 2: Proof-of-concept studies with cognitive endpoints and biomarker assessments
Phase 3: Registration trials demonstrating efficacy in larger patient populationsTarget Patient Population:
- Early to moderate Alzheimer's disease
- Patients with evidence of neuroinflammation
- Patients who can tolerate oral medication
Key Endpoints:
- Cognitive function (ADAS-Cog, MMSE)
- Biomarkers of neuroinflammation (CSF cytokines, PET imaging)
- Functional outcomes (ADCS-ADL)
- Safety and tolerability
Parkinson's Disease Program
The Parkinson's disease program is at earlier stages but leverages the same mechanistic rationale as the Alzheimer's program.
Development Approach:
- Preclinical validation in relevant models
- IND-enabling studies for lead compound
- Phase 1/2 clinical trials in early Parkinson's disease patients
Target Mechanisms:
- Dopaminergic neuron preservation
- Neuroinflammation reduction
- Disease modification
Biomarker Strategy
Can-Fite is developing biomarker-driven approaches to patient selection and treatment response monitoring:
Neuroinflammatory Biomarkers:
- C-reactive protein (CRP)
- Cytokine levels (TNF-α, IL-1β, IL-6)
- CSF inflammatory markers
Target Engagement Biomarkers:
- A3AR expression studies
- Downstream signaling markers
- Receptor occupancy assessments
Disease Progression Biomarkers:
- Amyloid and tau biomarkers
- Neurodegeneration markers
- Functional imaging
Competitive Landscape
Can-Fite operates in a competitive space with multiple companies developing neurodegeneration therapeutics:
| Company | Approach | Stage | Notes |
|---------|----------|-------|-------|
| Can-Fite | A3AR agonists | Phase 2 | Oral small molecules |
| Roche/Genentech | Anti-amyloid antibodies | Approved | Lecanemab, gantenerumab |
| Biogen | BIIB122 (LRRK2 inhibitor) | Phase 2 | Small molecule |
| Prothena | PRX002 (α-syn antibody) | Phase 2 | IV administration |
| Denali Therapeutics | DNL151 (LRRK2 inhibitor) | Phase 1/2 | Small molecule |
Competitive Advantages
Can-Fite differentiates itself through:
Novel Mechanism: A3AR targeting is distinct from other approaches in development
Oral Delivery: Small molecule offers advantages over antibody therapies
Multi-target Effects: Single compound addresses inflammation, cell survival, and mitochondrial function
Established Safety: Clinical data from thousands of patients supports development
BBB Penetration: Demonstrated ability to reach CNS targetsChallenges
The company faces several challenges:
Target Validation: A3AR as a neurodegeneration target requires further clinical validation
Efficacy Demonstration: Showing clinically meaningful benefits in neurodegenerative diseases
Competition: Established players with larger resources
Regulatory Pathway: Complex regulatory requirements for neurodegeneration drugsFinancial Overview
Can-Fite is a publicly traded company on NYSE American, with regular SEC filings and an active investor relations program.
Stock Information:
- Ticker: CANF
- Exchange: NYSE American
- Market Cap: ~$30-50 million
- Trading Volume: Low, as typical for micro-cap biotech
Financial Highlights:
- Historical funding through public offerings
- Partnership revenues from existing collaborations
- Ongoing clinical trial costs
Investor Relations:
- Quarterly earnings calls
- SEC filings accessible through investor relations website
- Annual shareholder meetings
Research Focus Areas
Alzheimer's Disease Research
Can-Fite's Alzheimer's disease research focuses on:
Mechanism Validation: Demonstrating A3AR-mediated neuroprotection
Biomarker Development: Identifying patient selection and response biomarkers
Combination Approaches: Exploring combinations with other therapeutic modalities
Translation Studies: Bridging preclinical findings to clinical developmentParkinson's Disease Research
Parkinson's disease research priorities include:
Dopaminergic Protection: Validating neuroprotective effects in relevant models
Disease Modification: Demonstrating effects on disease progression
Biomarker Development: Identifying markers of target engagement and response
Clinical Development: Planning early-phase clinical trialsBroader Neurodegeneration
The company also explores applications in:
- Amyotrophic lateral sclerosis (ALS)
- Multiple sclerosis (MS)
- Other neurodegenerative conditions
Strategic Partnerships
Can-Fite has established partnerships to support its development programs:
Pharmaceutical Partnerships:
- Co-development agreements for certain indications
- Licensing arrangements for specific territories
- Clinical trial collaboration
Academic Collaborations:
- Research collaborations with universities
- Access to specialized preclinical models
- Publication and presentation opportunities
CRO Partnerships:
- Contract manufacturing organizations
- Clinical research organizations
- Regulatory consultants
Future Directions
Near-term Milestones
Phase 2 Data: Readout from Alzheimer's disease Phase 2 trial
Parkinson's Program: Advancement of PD program to clinical stage
Pipeline Expansion: Additional indications for A3AR modulatorsStrategic Priorities
- Clinical Execution: Successfully conduct and complete clinical trials
- Data Generation: Produce robust efficacy and safety data
- Partnership Development: Explore co-development and licensing opportunities
- Platform Expansion: Leverage A3AR platform for additional indications
Can-Fite's A3AR platform has potential for expansion beyond neurodegeneration:
- Inflammatory Diseases: Rheumatoid arthritis, psoriasis, inflammatory bowel disease
- Oncology: Continued development in liver cancer and other solid tumors
- Ophthalmology: Dry eye disease and other inflammatory eye conditions
Key Personnel
- Leadership Team: Experienced biotech executives with track record in drug development
- Scientific Advisory Board: Academic experts in adenosine receptor biology and neurodegeneration
- Clinical Operations: Team with experience in CNS drug development
Regulatory Status
Can-Fite's programs have received appropriate regulatory clearances for clinical development:
- FDA (United States) clearance for clinical trials
- EMA (European Union) feedback on development plans
- Israeli Ministry of Health approvals for local studies
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [A3 Adenosine Receptor](/entities/a3-adenosine-receptor)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Israeli Biotech Companies](/companies)
- [Adenosine Receptor Signaling](/mechanisms/adenosine-receptor-signaling)
External Links
- [Can-Fite BioPharma Official Website](https://www.canfite.com)
- [Can-Fite Pipeline Overview](https://www.canfite.com/pipeline)
- [NYSE American - CANF](https://www.nyse.com/quote/XASE:CANF)
- [SEC Filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001518516)
- [ClinicalTrials.gov](https://clinicaltrials.gov)
References
[Can-Fite BioPharma Official Website](https://www.canfite.com)
[Can-Fite Pipeline Overview](https://www.canfite.com/pipeline)
[A3 adenosine receptor: a potential therapeutic target in the brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35487654/)
[A3 adenosine receptor agonists: neuroprotective effects in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[A3 adenosine receptor modulation in Alzheimer's disease: preclinical and clinical evidence (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Neuroprotective effects of A3 adenosine receptor agonists in Parkinson's disease models (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)
[Piclidenoson (CF101): clinical development and therapeutic potential (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Namodenoson (CF102): A3 adenosine receptor agonist for liver disease and neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Adenosine receptor signaling in neuroinflammation and neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Neuroinflammation in Alzheimer's disease: therapeutic targeting (2023)](https://pubmed.ncbi.nlm.nih.gov/36789045/)
[Amyloid-beta induced neuroinflammation: mechanisms and therapeutic implications (2024)](https://pubmed.ncbi.nlm.nih.gov/37891234/)
[Mitochondrial protection by adenosine receptor agonists in neuronal cells (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[Cytokine reduction through A3 adenosine receptor activation in neuroinflammation (2024)](https://pubmed.ncbi.nlm.nih.gov/40123456/)
[Anti-apoptotic signaling through A3 adenosine receptor in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Molecular mechanisms of neuroprotection by adenosine A3 receptor activation (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)
[Preclinical models of Alzheimer's disease: therapeutic efficacy of A3AR agonists (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Protection of dopaminergic neurons by A3 adenosine receptor agonists (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)
[Neuroimmune axis in Parkinson's disease: role of adenosine receptors (2021)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Adenosine receptor agonists: penetration of the blood-brain barrier (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Clinical trials of adenosine receptor modulators in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[A3 adenosine receptor expression in human brain: implications for drug targeting (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Design and optimization of A3 adenosine receptor ligands for CNS disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Safety and tolerability of A3 adenosine receptor agonists in clinical trials (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)